New therapeutic approach in inflammatory bowel disease

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue SUPPL. 1, 2009, Pages 33-35

  Papa, A ^a   Mocci, G ^a   Scaldaferri, F ^a   Bonizzi, M ^a   Felice, C ^a   Andrisani, G ^a   Gasbarrini, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adalimumab; Biologic agents; Inflammatory bowel disease; Infliximab; TNF

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASPERGILLOSIS; CELLULITIS; CLINICAL PROTOCOL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; ENTERITIS; HISTOPLASMOSIS; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGENICITY; INFECTION; INTERMETHOD COMPARISON; LISTERIOSIS; NEOPLASM; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SYSTEMIC MYCOSIS; T CELL LYMPHOMA; TREATMENT PLANNING; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65249161661     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. SCALDAFERRI F, FIOCCHI C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171-178.
2. BIANCONE L, ORLANDO A, KOHN A, COLOMBO E, SOSTEGNI R, ANGELUCCI E, RIZZELLO F, CASTIGLIONE F, BENAZZATO L, PAPI C, MEUCCI G, RIEGLER G, PETRUZZIELLO C, MOCCIARO F, GEREMIA A, CALABRESE E, COTTONE M, PALLONE F. Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study. Gut 2006; 55: 228-233.
3. ROSH JR, GROSS T, MAMULA P, GRIFFITHS A, HYAMS J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? Inflamm Bowel Dis 2007; 13: 1024-1030.
4. HANAUER SB, SANDBORN WJ, RUTGEERTS P, FEDORAK RN, LUKAS M, MACINTOSH D, PANACCIONE R, WOLF D, POLLACK P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
5. SANDBORN WJ, HANAUER SB, RUTGEERTS P, FEDORAK RN, LUKAS M, MACINTOSH DG, PANACCIONE R, WOLF D, KENT JD, BITTLE B, LI J, POLLACK PF. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007; 56: 1232-1239.
6. SANDBORN WJ, RUTGEERTS P, ENNS R, HANAUER SB, COLOMBEL JF, PANACCIONE R, D'HAENS G, LI J, ROSENFELD MR, KENT JD, POLLACK PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838.
7. SCHIFF MH, BURMESTER GR, KENTJD, PANGAN AL, KUPPER H, FITZPATRICK SB, DONOVAN C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894.
8. D'HAENS G, BAERT F, VAN ASSCHE G, CAENEPEEL P, VERGAUWE P, TUYNMAN H, DE VOS M, VAN DEVENTER S, STITT L, DONNER A, VERMEIRE S, VAN DE MIEROP FJ, COCHE JC, VAN DER WOUDE J, OCHSENKÜHN T, VAN BODEGRAVEN AA, VAN HOOTEGEM PP, LAMBRECHT GL, MANA F, RUTGEERTS P, FEAGAN BG, HOMMES D; BELGIAN INFLAMMATORY BOWEL DISEASE RESEARCH GROUP; NORTHHOLLAND GUT CLUB. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 2008; 371: 660-667.
9. OLDENBURG B, HOMMES D. Biological therapies in inflammatory bowel disease: Top-down or botton-up? Curr Opin Gastroenterol 2007; 23: 395-399.